Clinical Scorecard: Revised MSKCC Nomogram for Predicting Metastatic Progression and Its Implications for Active Surveillance: Insights from the Italian TPCP Cohort
At a Glance
Category
Detail
Condition
Prostate Cancer (PCa)
Key Mechanisms
Prognostic models for predicting metastatic progression and overall mortality.
Target Population
Men diagnosed with prostate cancer, particularly those eligible for active surveillance.
Care Setting
Oncology and Urology departments in hospitals.
Key Highlights
MSKCC nomogram outperformed D’Amico and CAPRA models in predicting metastatic PCa.
Using MSKCC thresholds increased AS eligibility from 7.8% to 57.0% without significantly raising metastatic risk.
The study analyzed 891 unselected PCa patients diagnosed between 2008 and 2013.
Guideline-Based Recommendations
Diagnosis
Utilize updated prognostic models for better risk stratification at diagnosis.
Management
Consider nomogram-based risk thresholds for active surveillance eligibility.
Monitoring & Follow-up
Regular follow-up for patients under active surveillance to monitor for signs of metastasis.
Risks
Evaluate the risk of metastatic progression when determining treatment options.
Patient & Prescribing Data
Men diagnosed with prostate cancer, particularly those under 85 years without systemic metastases at diagnosis.
Nomogram-based assessments can refine treatment decisions and enhance shared decision-making.
Clinical Best Practices
Implement risk-based eligibility criteria for active surveillance using the MSKCC nomogram.
Incorporate continuous risk assessment rather than broad risk categories.
by Nicolas Destefanis, Daniela Zugna, Valentina Fiano, Renata Zelic, Michelangelo Fiorentino, Francesca Giunchi, Piero Fariselli, Mauro Giulio Papotti, Paola Cassoni, Marco Oderda, Paolo Gontero, Luca Lianas, Mauro Del Rio, Giuseppe Carlo Iorio, Umberto Ricardi, Olof Akre, Andreas Pettersson, Lorenzo Richiardi
